Tacrine (Cognex)
Executive Summary
Warner-Lambert acquires data on the Alzheimer's disease treatment from a three-month double-blind, placebo-controlled crossover clinical trial conducted by U.K.-based Shire Pharmaceutical. The results will be used to supplement Warner-Lambert's NDA, which is "in the final stages of preparation" and is on schedule to be filed with FDA in June. Terms of the Shire transaction were not made public.